N/A
18 Years
N/A
18 Years
N/A
Open (Enrolling)
Both
Hypertension, Renal Function, Insulin Sensitivity, Renal Cell Carcinoma
Both
Hypertension, Renal Function, Insulin Sensitivity, Renal Cell Carcinoma
Trial Information
Inclusion Criteria:
- Subject is able and willing to sign the Informed Consent Form
- Age 18 years or older
- WHO performance status 0-2
- Life expectancy ≥ 12 weeks
- mRCC patients in which the treatment of choice is sunitinib
Exclusion Criteria:
- Use of corticosteroids
- Any evidence of severe or uncontrolled diseases other than renal cell carcinoma eg,
unstable or uncompensated respiratory, cardiac, hepatic or renal disease.
- Known risk of the patient transmitting HIV, hepatitis B or C via infected blood
- Patients being treated with oral anticoagulants if to be included in group A.
Type of Study:
Observational
Study Design:
Time Perspective: Prospective
Outcome Measure:
Endothelial function
Outcome Description:
Group A: Vasomotor response to intra-arterially administered doses of acetylcholine and nitroprusside before and after start sunitinib
Outcome Time Frame:
2 weeks
Safety Issue:
No
Authority:
Netherlands: The Central Committee on Research Involving Human Subjects (CCMO)
Study ID:
SUMAVA
NCT ID:
NCT01227213
Start Date:
November 2010
Completion Date:
November 2014
Related Keywords:
- Hypertension
- Renal Function
- Insulin Sensitivity
- Renal Cell Carcinoma
- Carcinoma
- Carcinoma, Renal Cell
- Hypertension
- Insulin Resistance
Name | Location |
|---|
